Product
소개
AvaBridge ELISA For Avastin Biosimilar Comparison
Complete kit for the systematic 3-D conformational comparability analysis of
Avastin biosimilar molecule to Bevacizumab (Avastin trade name).
Bevacizumab is a humanized monoclonal antibody, produced by Genentech, that inhibits vascular
endothelial growth factor A (VEGF-A). VEGF-A is a chemical signal that stimulates angiogenesis in a
variety of diseases, especially in cancer. Bevacizumab was the first clinically available angiogenesis
inhibitor in the United States and was approved by the U.S. Food and Drug Administration (FDA)
for certain metastatic cancers. It received its first approval in 2004 for combination use with standard
chemotherapy for metastatic colon cancer.
This kit will allow for conformational comparison between Avastin Biosimilars and authentic Bevacizumab.
주문정보
AB000201 AvaBridge ELISA (for Avastin Biosimilar Comparison) 1 Kit
관련자료